Last updated: September 8, 2026
Quazepam is a mature, low-volume benzodiazepine hypnotic with limited commercial momentum. The U.S. product, Doral, was approved in 1985 and has long since lost meaningful patent and regulatory exclusivity. Current market value is concentrated in generic quazepam tablets, where demand is constrained by clinical substitution, controlled-substance requirements, safety warnings, and competition from newer insomnia therapies. Public sources do not disclose standalone quazepam revenue, current unit sales, or a reliable market-size estimate.
What is the current market status of quazepam?
Quazepam is an oral benzodiazepine indicated for short-term treatment of insomnia. It is marketed in the United States as 7.5 mg and 15 mg tablets under generic labeling. The original brand, Doral, was associated with Schering-Plough and later commercial rights holders, but the brand has not maintained a significant current U.S. commercial presence.
| Attribute |
Quazepam status |
| Active ingredient |
Quazepam |
| Drug class |
Benzodiazepine hypnotic |
| U.S. brand |
Doral |
| Original U.S. approval |
1985 |
| FDA application |
NDA 018530 |
| Dosage form |
Immediate-release oral tablet |
| Common strengths |
7.5 mg and 15 mg |
| Controlled-substance class |
Schedule IV |
| Primary indication |
Insomnia |
| Current market structure |
Generic and limited-volume |
| Standalone revenue disclosure |
Not publicly reported |
| Patent position |
No meaningful remaining originator exclusivity identified |
| Main commercial constraints |
Safety, dependence risk, generic substitution, limited prescribing |
The FDA labeling describes quazepam as a long-acting benzodiazepine with active metabolites and warns about abuse, misuse, addiction, physical dependence, withdrawal, and central nervous system depression.[1] These characteristics reduce its attractiveness relative to shorter-acting or non-benzodiazepine insomnia treatments.
When did quazepam lose patent and regulatory exclusivity?
Quazepam’s original market exclusivity expired decades ago. The 1985 approval places the product well beyond the effective life of any original compound or formulation patents that could have supported current commercial exclusivity.
The U.S. regulatory timeline is broadly as follows:
| Event |
Approximate timing |
Commercial effect |
| U.S. approval of Doral |
1985 |
Originator launch |
| Original patent and regulatory protection period |
Late 1980s to 1990s |
Originator protection |
| Generic competition |
After original exclusivity period |
Price and share erosion |
| Current period |
2020s |
Mature generic market |
Patent term rules changed materially after the Hatch-Waxman Act and later patent-term reforms. A patent tied to a 1985 approval would not ordinarily create a current blocking right unless a later, independently issued patent covered a formulation, method of use, or manufacturing process. No such current quazepam patent position appears to support a material U.S. exclusivity strategy.
What patents protect quazepam?
No current patent estate with meaningful commercial blocking power is apparent from the public regulatory profile of quazepam. The original product’s protection would have covered the active compound, pharmaceutical composition, or use, but those rights are too old to support present-day branded exclusivity.
Compound and composition patents
Quazepam is an established small molecule. Any foundational compound patent associated with its discovery would have expired long ago. Generic manufacturers therefore do not face the type of active-molecule patent barrier that applies to recently approved small-molecule drugs.
Formulation patents
Public FDA labeling and the established product profile do not indicate a commercially significant extended-release, abuse-deterrent, transdermal, injectable, or other differentiated quazepam formulation. The marketed product is an immediate-release tablet. That limits the opportunity to create a new formulation-based franchise.
Method-of-use patents
Quazepam’s principal indication is insomnia. The indication is mature, and the product is not associated with a recently approved disease-specific use that could generate new method-of-use exclusivity. Any historical use patents would likely have expired or become commercially irrelevant.
Manufacturing and process protection
Quazepam may remain subject to ordinary manufacturing know-how, supplier qualifications, analytical methods, and controlled-substance handling requirements. Those measures can increase entry costs but do not appear to create a durable market monopoly. Manufacturing know-how is distinct from an enforceable, commercially blocking patent estate.
What is the FDA regulatory status of quazepam?
Quazepam remains a prescription benzodiazepine hypnotic regulated by the FDA. Its labeling includes boxed warnings for abuse, misuse, addiction, dependence, and withdrawal reactions.[1] The FDA has also issued class-wide benzodiazepine labeling updates addressing these risks.[2]
The product’s regulatory profile includes:
- Prescription-only distribution.
- Schedule IV controlled-substance status under the Controlled Substances Act.
- Restrictions associated with prescribing, dispensing, recordkeeping, and inventory control.
- Warnings concerning concomitant use with opioids and other central nervous system depressants.
- Risk of next-day impairment because quazepam has a long-acting metabolite.
- Limits on treatment duration because of dependence and tolerance risks.
These requirements do not prevent generic marketing, but they narrow the prescriber base and raise compliance costs for manufacturers, distributors, and pharmacies.
What is the Orange Book status of quazepam?
Quazepam was listed historically through the Doral NDA, identified in FDA records as NDA 018530. The key commercial issue is not Orange Book exclusivity but the product’s mature generic status.
| Orange Book issue |
Quazepam implication |
| Reference listed drug |
Doral historically associated with NDA 018530 |
| Active exclusivity |
None expected from the 1985 approval |
| Current patent barrier |
No material blocking estate identified |
| Generic pathway |
Abbreviated New Drug Application pathway |
| Paragraph IV significance |
Low relative to newly launched products |
| Commercial value of Orange Book listings |
Primarily reference-product and substitution relevance |
A generic applicant could challenge a listed patent through a Paragraph IV certification if a relevant patent were listed. For quazepam, the economic importance of such a challenge is limited because the underlying product is old and the market is small. Publicly identified recent Paragraph IV litigation involving quazepam is not a material feature of the product’s current competitive landscape.
Which companies are challenging quazepam patents?
No major current patent challenger has been publicly associated with a commercially important quazepam Paragraph IV campaign. Generic competition appears to have developed through the ordinary abbreviated-approval pathway rather than through a high-value patent dispute.
Historically, generic drug manufacturers associated with mature benzodiazepine products have included companies such as Actavis, Teva, West-Ward or Hikma, and other contract or private-label suppliers. Manufacturer participation can change because of supply decisions, product discontinuations, acquisition activity, and FDA establishment status. The presence of an approved generic product does not guarantee continuous commercial availability.
No major settlement agreement, reverse-payment arrangement, or current patent litigation has shaped quazepam’s U.S. market in the way seen with high-revenue branded medicines.
How strong is the quazepam patent estate?
The patent estate is commercially weak.
| Patent-estate factor |
Assessment |
| Foundational molecule protection |
Expired |
| Original product protection |
Expired or commercially obsolete |
| Active formulation protection |
No material current estate identified |
| Method-of-use protection |
No current high-value exclusivity identified |
| Manufacturing barriers |
Operational rather than monopoly-forming |
| Litigation leverage |
Low |
| Generic entry risk |
High |
| Ability to support premium pricing |
Very low |
Quazepam’s principal defense is not intellectual property. It is the friction of a small controlled-substance market, low expected volume, regulatory compliance, and limited commercial interest. Those factors can discourage new entrants, but they do not protect the product from generic substitution if a manufacturer elects to supply it.
How does quazepam compare with competing insomnia drugs?
Quazepam competes with benzodiazepines, non-benzodiazepine hypnotics, orexin receptor antagonists, sedating antidepressants, and newer insomnia products. It has a weaker commercial profile than products with active patents, strong consumer recognition, or differentiated safety positioning.
| Product category |
Examples |
Competitive effect on quazepam |
| Benzodiazepine hypnotics |
Temazepam, estazolam, triazolam |
Direct class competition |
| Non-benzodiazepine hypnotics |
Zolpidem, zaleplon, eszopiclone |
Established generic alternatives |
| Orexin antagonists |
Suvorexant, lemborexant, daridorexant |
Newer branded alternatives with differentiated mechanisms |
| Sedating antidepressants |
Doxepin and off-label alternatives |
Substitute prescribing options |
| Behavioral therapy |
Cognitive behavioral therapy for insomnia |
Reduces reliance on chronic hypnotic use |
Quazepam’s long half-life can be clinically useful for sleep maintenance but also increases concerns about residual sedation and next-day impairment. Shorter-acting products may be preferred when clinicians seek to reduce morning impairment. Orexin antagonists can compete for patients and prescribers seeking non-benzodiazepine mechanisms, although their branded prices are higher.
What generic entry risks exist for quazepam?
Generic entry risk is structurally high because the product has no meaningful current exclusivity. The main market risk is not a sudden patent cliff. It is continued erosion through low-cost generic substitution and possible supplier exit.
Generic launch scenarios
Stable low-volume supply. One or more manufacturers continue supplying tablets, with modest price changes and periodic shortages.
Single-source exposure. A manufacturer exits, leaving a small number of suppliers. Prices can rise temporarily, but the market remains unattractive for large-scale investment.
Re-entry by a generic manufacturer. A company enters or resumes supply if wholesaler demand, reimbursement, or shortage conditions improve.
Commercial discontinuation. Manufacturers withdraw because volume is too low to justify controlled-substance compliance, pharmacovigilance, inventory, and distribution costs.
The most relevant risk for patients and buyers is availability volatility rather than patent-based delay.
What is the financial trajectory for quazepam?
No public company reports quazepam revenue as a separate line item. The drug’s financial trajectory is therefore best assessed through market structure rather than a reported sales series.
| Financial factor |
Direction |
| Branded revenue |
Negligible or absent in the current U.S. market |
| Generic pricing |
Low and substitution-driven |
| Prescription growth |
Structurally limited |
| Gross-margin potential |
Constrained by low price and modest volume |
| Regulatory cost burden |
High relative to likely revenue |
| Licensing value |
Low unless bundled with a broader CNS portfolio |
| Acquisition value |
Primarily supply-chain or portfolio value |
| Forecast visibility |
Poor because company-level reporting is absent |
Quazepam does not appear to be a material revenue contributor for a major pharmaceutical company. Any current revenue is likely distributed across generic manufacturers and private-label suppliers. The product may have niche value for a company with existing controlled-substance infrastructure, but it is unlikely to support standalone commercial investment.
Revenue exposure for manufacturers
For a generic manufacturer, quazepam revenue exposure is more likely to be operational than strategic. The product can contribute incremental sales if manufacturing capacity is already available, but it is unlikely to justify dedicated facilities or a major sales force. A supplier may rationally keep the product in its portfolio to maintain pharmacy relationships or serve a niche demand base.
Licensing and transaction value
No major recent licensing deal centered on quazepam is publicly identified. A transaction involving quazepam would more likely be structured as part of a broader portfolio transfer containing multiple mature CNS products. Standalone licensing economics would be constrained by:
- No meaningful patent exclusivity.
- Generic price competition.
- Controlled-substance compliance.
- Small prescriber and patient base.
- Limited potential for label expansion.
- Uncertain supply continuity.
What patent litigation and settlement agreements affect quazepam?
No material active patent litigation or settlement agreement is publicly associated with quazepam’s current U.S. market position. The product’s age and generic status reduce the economic incentive for originator litigation.
The relevant legal risks are instead:
- Controlled-substance compliance.
- Product liability involving sedation, falls, dependence, or withdrawal.
- Manufacturing and quality-system violations.
- Advertising or promotional compliance.
- Distribution and monitoring obligations.
- Supply interruption and shortage-related exposure.
These risks can affect cost and availability without creating exclusivity.
What geographic markets are relevant to quazepam?
The United States is the clearest reference market because of the FDA approval, Doral history, and established generic framework. Quazepam has also had presence in selected international markets, including Japan, but regulatory status, brand ownership, availability, and reimbursement can vary by country.
International commercial analysis should account for:
- Country-specific marketing authorizations.
- Local controlled-substance rules.
- Different treatment guidelines for insomnia.
- National reimbursement and reference-pricing systems.
- Product discontinuation decisions by local license holders.
- Pharmacovigilance obligations.
Geographic expansion is unlikely to create substantial value without a differentiated formulation or a new clinical positioning.
What is the outlook for quazepam?
Quazepam is a mature maintenance product with limited growth prospects. Demand should remain niche and may decline gradually as clinicians favor behavioral therapy, non-benzodiazepine options, or newer insomnia medicines. Generic availability can persist because the drug has an established approval pathway, but supply may remain uneven.
The product’s strongest commercial attributes are its known clinical profile, established regulatory history, and potential fit within a generic CNS portfolio. Its weakest attributes are the absence of patent protection, low pricing, controlled-substance obligations, safety concerns, and limited opportunity for innovation.
Key Takeaways
- Quazepam is a 1985-approved benzodiazepine hypnotic marketed historically as Doral and now primarily associated with generic tablets.
- The product has no meaningful current patent or regulatory exclusivity identified.
- NDA 018530 is the key historical U.S. reference application.
- Paragraph IV litigation, patent settlements, and major current challenges are not material features of the market.
- The FDA safety profile limits prescribing and increases compliance costs.
- Standalone revenue, market share, and manufacturer-level sales are not publicly disclosed.
- Financial value is likely limited to incremental generic portfolio revenue.
- The principal commercial risk is supplier withdrawal or intermittent availability, not delayed generic entry.
- Quazepam is unlikely to support a significant branded relaunch without a new formulation, indication, or delivery technology.
Frequently Asked Questions
Is quazepam still available in the United States?
Generic quazepam tablets have been listed in U.S. drug databases, but commercial availability can vary by manufacturer, wholesaler inventory, and pharmacy purchasing decisions. The former Doral brand does not represent a significant current branded franchise.
Is quazepam a controlled substance?
Yes. Quazepam is a Schedule IV benzodiazepine under U.S. controlled-substance rules. Prescribing and dispensing are subject to controlled-substance compliance requirements.
Does quazepam have an active Orange Book patent?
No material active patent exclusivity associated with quazepam is identified from its mature regulatory history. Any current Orange Book relevance is primarily tied to the reference product and generic approval framework.
Can a company launch a generic quazepam product?
A company may seek approval through the abbreviated new drug application pathway if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and controlled-substance compliance. Commercial launch depends on supply economics and market demand.
Is quazepam a good pharmaceutical licensing opportunity?
As a standalone asset, quazepam has limited licensing value. Its economics may improve only when bundled with other mature CNS products, existing controlled-substance infrastructure, or a differentiated formulation with separate intellectual-property protection.
References
-
U.S. Food and Drug Administration. (2023). Quazepam tablets prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2020). FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. FDA Drug Safety Communication.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, NDA 018530. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Drug Enforcement Administration. (2023). Controlled substance schedules. U.S. Department of Justice.
